通过结构启用发现了碳酸酸前药物,作为潜在的向谷氨酸酶C的强效抑制剂
Hanyu Sun1, Shize Li1, Chengxia Mao2
1State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, PR China; Beijing Key Laboratory of Active Substances Discovery and Drugability Evaluation, Department of Medicinal Chemistry, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, PR China.
研究人员开发了针对谷氨酸酶C (GAC),癌症代谢中的关键酶的新型前期药物. 产药16通过抑制GAC和阻断谷氨胺代谢,表现出强大的抗癌活性.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 谷氨酸酶C (GAC) 是谷氨酸溶解中的关键酶,也是癌症的治疗点.
- GAC的线粒体局部化对药物输送和疗效提出了挑战.
- 之前的研究已经确定了GAC的全囊中一个基本的热点,用于增强结合.
研究的目的:
- 设计和开发针对 GAC 基本热点的新型酸性衍生物和前期药物.
- 为了改善GAC抑制剂的脂性和细胞输送.
- 评估开发的化合物的抗增殖和抗瘤疗效.
主要方法:
- 基于CB839架构的酸性衍生品的设计,针对GAC基本热点.
- 从碳酸抑制剂开发前药物,以增强脂友性.
- 使用A549细胞进行体外抗增殖试验.
- 使用A549异种移植小鼠模型进行体内抗瘤研究.
主要成果:
- 产物16对A549细胞 (IC50 = 2.45 nM) 具有显著的抗增殖活性,稳定性良好.
- 产品药16通过抑制谷氨酸代谢,有效调节细胞代谢物和增加活性氧物种.
- 在A549异种移植模型中,Prodrug 16在体内表现出强大的抗瘤活性.
结论:
- 产药16是一种高效的谷氨酸酶C抑制剂,具有有前途的治疗潜力.
- 开发的前药物策略为下一代GAC向癌症治疗提供了一种新的方法.
- 通过改进的传递系统,针对GAC基本热点可以克服癌症治疗方面的挑战.
相关概念视频
Enzyme Inhibition
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Antiepileptic Drugs: Glutamate Antagonists
Ligand Binding and Linkage
Prodrugs
Prodrugs help overcome...


